Bioarctic Neuroscience Ab

Eva Nordström

Lars Lannfelt

Alex Kasrayan

Valentina Screpanti Sundquist

Mats Holmquist

Monica Ekberg

In an in vivo method for detecting &#x3b1;-synuclein protofibrils in human tissue, an antibody or fragment thereof is administered to a human. The antibody or fragment is labelled with a detectable label. A complex formed between the antibody or fragment and &#x3b1;-synuclein protofibrils in the human tissue is detected. The antibody or fragment has high affinity for human &#x3b1;-synuclein protofibrils and low affinity for &#x3b1;-synuclein monomers and has a combination of three specified variable heavy (VH) CDR sequences and three specified variable light (VL) CDR sequences.

Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other &#x3b1;-synucleinopathies

Antibodies and fragments thereof have high affinity for human &#x3b1;-synuclein protofibrils and low binding of &#x3b1;-synuclein monomers, wherein the antibodies or fragments have specified Complementarity Determining Region (CDR) sequences. Compositions comprise such an antibody or fragment and methods of detecting &#x3b1;-synuclein protofibrils use such an antibody or fragment. In further embodiments, methods of preventing, delaying onset of or treating a neurodegenerative disorder with &#x3b1;-synuclein pathology comprise administering such an antibody or fragment, and such an antibody or fragment is used in the manufacture of a pharmaceutical composition for treatment of a neurodegenerative disorder with &#x3b1;-synuclein pathology. Such an antibody or fragment is used in the diagnosis or monitoring of the development of a neurodegenerative disorder with &#x3b1;-synuclein pathology, and in methods for reducing or inhibiting &#x3b1;-synuclein aggregation by administration of such an antibody or fragment.

Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for Parkinson's disease, dementia with lewy bodies and other &#x3b1;-synucleinopathies

Protofibril-binding antibodies and their use in thereapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies

Growing community of inventors

Rönninge, Sweden

Eva Nordström